A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer

Growth Factors

Volumn 17, Issue 4, 2000, Pages 287-300

  Davis, Ian D ^a,d   Maher, Darryl W ^a,b,c   Cebon, Jonathan S ^a,d   Green, Michael D ^e   Fox, Riachard M ^c   McKendrick, Joseph J ^d   Rybak, Mary Ellen ^e   Boyd, Andrew W ^b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Clinical trial; Cytokines; Immunotherapy; Interleukin 4; Pharmacokinetics

Indexed keywords

ALKALINE PHOSPHATASE; RECOMBINANT INTERLEUKIN 4;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FACE PAIN; FATIGUE; FEMALE; FEVER; FLUID RETENTION; HEADACHE; HEMANGIOPERICYTOMA; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LETHARGY; MALE; MELANOMA; MESOTHELIOMA; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CARCINOMA; SIDE EFFECT; TIME; TREATMENT OUTCOME; VERTIGO; VOMITING; WEIGHT GAIN;

EID: 0034006840     PISSN: 08977194     EISSN: None     Source Type: Journal    
DOI: 10.3109/08977190009028972     Document Type: Article

References (69)

1. Atkins, M.B., Vachino, G., Tilg, H.J., Karp, D.D., Robert, N.J., Kappler, K. and Mier, J.W. (1992) Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J. Clin. Oncol. 10, 1802-1809.
2. Barut, B.A., Cochran, M.K., O'Hara, C. and Anderson, K.C. (1990) Response patterns of hairy cell leukemia to B-cell mitogens and growth factors. Blood 76, 2091-2097.
3. Begley, C.G. (1996) Human progenitor cell assays. In: Morstyn G. and Sheridan W.P. (Eds.) Cell Therapy: Stem Cell Transplantation, Gene Therapy and Cellular Immunotherapy. Cambridge University Press.
4. Blankenstein, T., Li, W., Müller, W. and Diamantstein, T. (1990) Retroviral interleukin 4 gene transfer into an interleukin 4-dependent cell line results in autocrine growth but not in tumorigenicity. Eur. J. Immunol. 20, 935-938.
5. Broxmeyer, H.E., Hu, L., Cooper, S., Tushinski, R., Mochizuki, D., Rubin, B.Y., Gillies, S. and Williams, D.E. (1988) Synergistic effects of purified recombinant human and murine B cell growth factor-1/IL-4 on colony formation in vitro by hematopoietic progenitor cells. J. Immunol. 141, 3852-3862.
6. Chakraborty, N.G., Sporn, J.R., Tortora, A.F., Kurtzman, S.H., Yamase, H., Ergin, M.T. and Mukherji, B. (1998) Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol. Immunother. 47, 58-64.
7. Coffman, R.L., Ohara, J., Bond, M.W., Carty, J., Zlotnik, A. and Paul, W.E. (1986) B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J. Immunol. 136, 4538-4541.
8. Colgan, S.P., Resnick, M.B., Parkos, C.A., Delp-Archer, C., McGuirk, D., Bacarra, A.E., Weller, P.F. and Madara, J.L. (1994) IL-4 directly modulates function of a model human intestinal epithelium. J. Immunol. 153, 2122-2129.
9. Crawford, R., Finbloom, M., Ohara, J., Paul, W.E. and Meltzer, M. (1987) B cell stimulatory factor 1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J. Immunol. 139, 135-141.
10. Davis, I., Maher, D., Cebon, J., Dyer, W., McKendrick, J., Begley, G., Woodruff, R., Green, M., Fox, R., Rallings, M., Bonnem, E., Boyd, A. and Morstyn, G. (1991) Pharmacokinetic and clinical studies of interleukin-4 (IL-4) in patients with malignancy (abstract). Proc. Am. Soc. Clin. Oncol. 10, 287.
11. de Vries, J.E. (1992) Interleukin-4. In: Aggarwal B.B. and Gutterman J.U. (Eds.) Human Cytokines. Handbook for Basic and Clinical Research. Blackwell Scientific Publications, Boston, MA, pp. 113-129.
12. DeLuca, E., Sheridan, W.P., Watson, D., Szer, J. and Begley, C.G. (1992) Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br. J. Cancer 66, 893-899.
13. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R.C. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
14. Ghosh, A.K., Smith, N.K., Prendiville, J., Thatcher, N., Crowther, D. and Stern, P.L. (1993) A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: Immunological studies. Eur. Cytokine Netw. 4, 205-211.
15. Gilleece, M.H., Scarffe, J.H., Ghosh, A., Heyworth, C.M., Bonnem, E., Testa, N., Stern, P. and Dexter, T.M. (1992) Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections - a phase I dose toxicity trial. Br. J. Cancer 66, 204-210.
16. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M. and Pardoll, D.M. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
17. Grimm, E.A., Mazumder, A., Zhang, H.Z. and Rosenberg, S.A. (1992) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841.
18. Henschler, R., Mantovani, L., Oster, W., Lubbert, M., Lindemann, A., Mertelsmann, R. and Herrmann, F. (1990) Interleukin-4 regulates mRNA accumulation of macrophage-colony stimulating factor by fibroblasts: synergism with interleukin-1 beta. Br. J. Haematol. 76, 7-11.
19. Herrmann, F., Andreeff, M., Gruss, H.-J., Brach, M.A., Lübbert, M. and Mertelsmann, R. (1991) Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 78, 2070-2074.
20. Hillman, G.G., Puri, R.K., Kukuruga, M.A., Pontes, J.E. and Haas, G.P. (1994) Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) on human renal cell carcinoma. Clin. Exp. Immunol. 96, 476-483.
21. Hoon, D.S., Hayashi, Y., Morisaki, T., Foshag, L.J. and Morton, D.L. (1993) Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells. Cancer Immunol. Immunother. 37, 378-384.
22. Hoon, D.S.B., Okun, E., Banez, M., Irie, R.F. and Morton, D.L. (1991) Interleukin 4 alone and with γ-interferon or α-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res. 51, 5687-5693.
23. Howard, M., Farrar, J., Hilfiker, M., Johnson, B., Takatsu, K., Hamaoka, T. and Paul, W.E. (1982) Identification of a T-cell derived B cell growth factor distinct from interleukin-2. J. Exp. Med. 155, 914-923.
24. Imai, Y., Nara, N., Tohda, S., Nagata, K., Suzuki, T., Nagasawa, M., Murohashi, I. and Aoki, N. (1991) Antiproliferative and differentiative effects of recombinant interleukin-4 on a granulocyte colony-stimulating factor-dependent myeloblastic leukemic cell line. Blood 78, 471-178.
25. Ishizaka, A., Sakiyama, Y., Nakanishi, M., Tomizawa, K., Oshika, E., Kojima, K., Taguchi, Y., Kandil, E. and Matsumoto, S. (1990) The inductive effect of interleukin-4 on IgG4 and IgE synthesis in human peripheral blood lymphocytes. Clin. Exp. Immunol. 79, 392-396.
26. Karray, S., Kautry Varsat, A., Tsudo, M., Merle Beral, H., Debre, P. and Galanaud, P. ( 1990) IL-4 inhibits the expression of high affinity IL-2 receptors on monoclonal human B cells. J. Immunol. 145, 1152-1158.
27. Lahm, H., Schnyder, B., Wyniger, J., Borbenyi, Z., Yilmaz, A., Car, B.D., Fischer, J.R., Givel, J.-C. and Ryffel, B. (1994) Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int. J. Cancer 59, 440-447.
28. Leach, M.W., Snyder, E.A., Sinha, D.P. and Rosenblum, I.Y. (1997) Safety evaluation of recombinant human interleukin-4. I. Preclinical studies. Clin. Immunol. Immunopathol. 83, 8-11.
29. Lotze, M.T., Rubin, J.T., Carty, S., Edington, H., Ferson, P., Landreneau, R., Pippin, B., Posner, M., Rosenfelder, D., Watson, C., Carlos, T., Kirkwood, J., Lembersky, B., Logan, T., Rosenstein, M., Rybak, M.E., Whiteside, T., Elder, E., Moen, R.C., Jacob, W., Chen, Y., Rinkus, R.L. and Bryant, J. (1994) Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Human Gene Ther. 5, 41-55.
30. Lotze, M.T., Shurin, M., Davis, I., Amoscato, A. and Storkus, W.J. (1997) Dendritic cell based therapy of cancer. In: Ricciardi-Castagnoli P. (Ed.) Dendritic Cells in Fundamental and Clinical Immunology. Plenum Press, New York, pp. 551-569.
31. Maher, D., Boyd, A., McKendrick, J., Begley, G., Lieschke, M., Green, M., Fox, R., Rallings, M., Bonnem, E. and Morstyn, G. (1990a) Rapid response of B-cell malignancies induced by interleukin-4 (IL-4) (abstract). Blood 76, 152a.
32. Maher, D.W., Pike, B.L. and Boyd, A.W. (1990b) The response of human B cells to interleukin 4 is determined by their stage of activation and differentiation. Scand. J. Immunol. 32, 631-640.
33. Maher, D.W., Davis, I., Boyd, A.W. and Morstyn, G. (1991) Human interleukin-4: an immunomodulator with potential therapeutic applications. Prog. Growth Factors Res. 3, 43-56.
34. Margolin, K., Aronson, F.R., Sznol, M., Atkins, M.B., Gucalp, R., Fisher, R.I., Sunderland, M., Doroshow, J.H., Ernest, M.L., Mier, J.W. et al. (1994) Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J. Immunother. Emphasis Tumor Immunol. 15, 147-153.
35. Markowitz, A., Kleinerman, E., Hudson, M., Itoh, K., LaPushin, R., Stewart, M. and Gutterman, J. (1989) Phase I study of recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer (abstract). Blood 74 (Suppl. 1), 146a.
36. Miller, A.B., Hoogstraten, B., Staquet, M. and Winkler, A. (1981) Reporting results of cancer treatment. Cancer 47, 207-214.
37. Mitchell, P.L.R., Clutterbuck, R.D., Powles, R.L., Lord, C.D., Morilla, R., Hiorns, L.R., Titley, J., Catovsky, D. and Millar, J.L. (1996) Interleukin-4 enhances the survival ofSCID mice engrafted with human B-cell precursor leukaemia. Blood 87, 4797-4803.
38. Modesti, A., Masuelli, L., Modica, A., D'Orazi, G., Scarpa, S., Bosco, M.C. and Forni, G. (1993) Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated rejection of a spontaneous murine adenocarcinoma. Int. J. Cancer 53, 988-993.
39. Morisaki, T., Yuzuki, D.H., Lin, R.T., Foshag, L.J., Morton, D.L. and Hoon, D.S.B. (1992) Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res. 52, 6059-6065.
40. Nair, S.K., Boczkowski, D., Morse, M., Cumming, R.I., Lyerly, H.K. and Gilboa, E. (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364-369.
41. Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
42. Newcom, S. R., Ansari, A.A. and Gu, L. (1992) Interleukin-4 is an autocrine growth factor secreted by the L-428 Reed-Sternberg cell. Blood 79, 191-197.
43. Noma, Y., Sideras, P., Naito, T., Bergstedt-Lindquist, S., Azuma, C., Severinson, E., Tanabe, T., Kinashi, T., Matsuda, F., Yaoita, Y. and Honjo, T. (1986) Molecular cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature 319, 640-656.
44. Ohe, Y., Podack, E.R., Olsen, K.J., Miyahara, Y., Ohira, R., Miura, K., Nishio, K. and Saijo, N. (1993) Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int. J. Cancer 53, 432-437.
45. Okabe, M., Kuni-eda, Y., Sugiwura, T., Tanaka, M., Miyagishima, I.T., Saiki, I., Minagawa, T., Kurosawa, M., Itaya, T. and Miyazaki, T. (1991) Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells. Blood 78, 1574-1580.
46. Olencki, T., Finke, J., Tubbs, R., Tuason, L., Greene, T., McLain, D., Swanson, S.J., Herzog, P., Stanley, J., Edinger, M., Budd, G.T. and Bukowski, R.M. (1996) Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy. J. Immunother. Emphasis Tumor Immunol. 19, 69-80.
47. Park, L.S., Friend, D., Sassenfeld, H.M. and Urdal, D.L. (1987) Characterization of the human B cell stimulatory factor 1 receptor. J. Exp. Med. 166, 476-488.
48. Paul, W.E. (1991) Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77, 1859-1870.
49. Pippin, B.A., Rosenstein, M., Jacob, W.F., Chiang, Y. and Lotze, M.T. (1994) Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Therapy 1, 35-42.
50. Platzer, C., Richter, G., Überla, K., Hock, H., Diamantstein, T. and Blankenstein, T. (1992) Interleukin-4-mediated tumor suppression in nude mice involves interferon-γ. Eur. J. Immunol. 22, 1729-1733.
51. Rubin, J.T. and Lotze, M.T. (1992) Acute gastric mucosal injury associated with the systemic administration of IL-4. Surgery 111, 274-280.
52. Sallusto, F. and Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118.
53. Smeland, E.B., Blomhoft, H.K., Funderud, S., Shalaby, M.R. and Espevik, T. (1989) Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J. Exp. Med. 170, 1463-1468.
54. Sosman, J.A., Fisher, S.G., Kefer, C., Fisher, R.I. and Ellis, T.M. (1994) A phase 1 trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann. Oncol. 5, 447-452.
55. Spits, H., Yssel, H., Paliard, X., Kastelein, R., Figdor, C. and de Vries, J.E. (1988) IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J. Immunol. 141, 29-36.
56. Taylor, C.W., Grogan, T.M. and Salmon, S.E. (1990) Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 75, 1114-1118.
57. Tepper, R.I., Coffman, R.L. and Leder, P. (1992) An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548-551.
58. Tepper, R.I., Pattengale, P.K. and Leder, P. (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512.
59. Thornhill, M.H. and Haskard, D.O. (1990) IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor, or IFN-γ. J. Immmunol. 145, 865-872.
60. Thornhill, M.H., Kyan-Aung, U. and Haskard, D.O. (1990) IL-4 regulates endothelial cell adhesiveness for T cells but not for neutrophils. J. Immunol. 144, 3060-3065.
61. Toi, M., Bicknell, R. and Harris, A.L. (1992) Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 52, 275-279.
62. Totpal, K. and Aggarwal, B. B. (1991) Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various cell lines. Cancer Res. 51, 4266-4270.
63. Trehu, E.G., Isner, J.M., Mier, J.W., Karp, D.D. and Atkins, M.B. (1993) Possible myocardial toxicity associated with interleukin-4 therapy. J. Immunother. 14, 348-351.
64. Tulpule, A., Joshi, B., DeGuzman, N., Espina, B.M., Mocharnuk, R., Prakash, O., Templeton, D., Levine, A.M. and Gill, P.S. (1997) Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma. Ann Oncol. 8, 79-83.
65. Vitetta, E.S., Ohara, J., Myers, C.D., Layton, J.E., Krammer, P.H. and Paul, W.E. (1985) Serological biochemical and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J. Exp. Med. 162, 1726-1731.
66. Vokes, E.E., Figlin, R., Hochster, H., Lotze, M. and Rybak, M.E. (1998) A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. Cancer J. Sci. Am. 4, 46-51.
67. Wong, H.L., Lotze, M.T., Wahl, L.M. and Wahl, S.M. (1992) Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes. J. Immunol. 148, 2118-2125.
68. Yokota, T., Otsuka, T., Mosmann, T., Banchereau, J., Defrance, T., Blanchard, J., DeVries, E., Lee, F. and Arai, K.-I. (1986) Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor-1, that expresses B-cell- and T-cell-stimulating activities. Prof. Natl. Acad. Sci. USA 83, 5894-5898.
69. Yu, J.S., Wei, M.X., Chiocca, E.A., Martuza, R.L. and Tepper, R. (1993) Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 53, 3125-3128.